首页|3D-STI对乳腺癌术后TRA治疗患者早期心肌毒性的效能评价

3D-STI对乳腺癌术后TRA治疗患者早期心肌毒性的效能评价

扫码查看
目的 探讨三维斑点追踪成像(3D-STI)技术对乳腺癌术后曲妥珠单抗(TRA)治疗相关早期心肌毒性的效能。方法 回顾性研究选择2020年1月至2022年12月该院接受TRA治疗并维持治疗的120例乳腺癌术后患者,分别在化疗前及化疗2、4、6个周期后进行常规超声和3D-STI技术检测。随访至2023年10月,以是否出现心肌毒性为临床结局分为心肌毒性组和无心肌毒性组。结合基线资料,使用单因素和多因素logistic回归分析确定心肌毒性的影响因素,应用受试者工作特征(ROC)曲线评估不同时间的3D-STI参数对心肌毒性的预测价值。结果 化疗前和化疗2个周期后心肌毒性组和无心肌毒性组整体纵向应变(GLS)、整体面积应变(GAS)、整体径向应变(GRS)、整体圆周应变(GCS)等3D-STI技术参数差异无统计学意义(P>0。05);化疗4个周期后和化疗6个周期后心肌毒性组GLS、GAS和GCS低于无心肌毒性组(P<0。05)。lo-gistic回归分析结果显示,化疗4个周期后GLS(OR=0。542,95%CI:0。424~0。694)、GAS(OR=0。580,95%CI:0。360~0。936)和GCS(OR=1。699,95%CI:1。035~2。790)与化疗6个周期后GLS(OR=0。534,95%CI:0。440~0。648)、GAS(OR=0。559,95%CI:0。347~0。901)和GCS(OR=1。613,95%CI:1。131~2。300)是乳腺癌术后TRA治疗心肌毒性的影响因素(P<0。05)。ROC曲线结果显示,化疗4个周期后GLS诊断临界值为-17。23%,AUC为0。645(95%CI:0。541~0。749);GCS诊断临界值为-19。22%,AUC为0。556(95%CI:0。444~0。668)。化疗6个周期后GLS诊断临界值为-17。82%,AUC为0。856(95%CI:0。786~0。927);GAS诊断临界值为-27。17%,AUC为0。994(95%CI:0。983~<1。000);GCS诊断临界值为-18。38%,AUC为0。842(95%CI:0。771~0。913)。结论 化疗4、6个周期后3D-STI参数可预测乳腺癌术后TRA治疗后的心肌毒性。
Assessment of efficiency of 3D-STI technology on early myocardial toxicity in patients with TRA treatment after breast cancer surgery
Objective To study the efficiency of 3D-STI technology on trastuzumab (TRA) treatment related early myocardial toxicity.Methods In a retrospective study,120 breast cancer postoperative patients receiving TRA treatment and maintenance therapy in this hospital from January 2020 to December 2022 were selected and conducted the routine ultrasound and 3D-STI technological examinations before chemotherapy,in 2,4,6 cycles of chemotherapy.Follow-up continued until October 2023.The patients were divided into the my-ocardial toxicity group and non-myocardial toxicity group according to whether or not developing myocardial toxicity.By combining with the baseline data,the univariate and multivariate logistic regression were em-ployed to analyze and determine the influencing factors of myocardial toxicity.The predictive value of 3D-STI parameters at different time points for myocardial toxicity was evaluated by using the receiver operating char-acteristic (ROC) curve.Results There was no statistically significant difference in 3D-STI technical parame-ters such as GLS,GAS,GCS and GRS before chemotherapy and in 2 cycles of chemotherapy between the myo-cardial toxicity group and the non-myocardial toxicity group (P>0.05);GLS,GAS and GRS after 4,6 cycles of chemotherapy in the myocardial toxicity group were lower than those in the non-myocardial toxicity group (P<0.05).The logistic regression analysis results showed that GLS (OR=0.542,95%CI:0.424-0.694),GAS (OR=0.580,95%CI:0.360-0.936) and GCS (OR=1.699,95%CI:1.035-2.790) after 4 cycles of chemotherapy,and GLS (OR=0.534,95%CI:0.440-0.648),GAS (OR=0.559,95%CI:0.347-0.901) and GCS (OR=1.613,95%CI:1.131-2.300) after 6 cycles of chemotherapy were the influencing factors of myocardial toxicity in TRA treatment after breast cancer surgery (P<0.05).The results of the ROC curve showed that after 4 cycles of chemotherapy,the diagnostic critical value of GLS was-17.23% and the area under the curve (AUC) was 0.645 (95%CI:0.541-0.749);the diagnostic critical value of GCS was-19.22% and AUC was 0.556 (95%CI:0.444-0.668).The GLS diagnostic critical value after 6 cycles of chemotherapy was-17.82%,and AUC was 0.856 (95%CI:0.786-0.927);the GAS diagnostic critical value was-27.17%,and AUC was 0.994 (95%CI:0.983-<1.000);the diagnostic critical value of GCS was-18.38%,and AUC was 0.842 (95%CI:0.771-0.913).Conclusion The 3D-STI parameters in 4,6 cycles of chemotherapy could predict the myocardial toxicity after TRA treatment after breast cancer surgery.

three-dimensional speckle tracking imagingtrastuzumabbreast cancermyocardial toxicity

田甜、袁媛、封雪、杨芦莎、陈醇

展开 >

重庆市中医院超声科,重庆 400021

三维斑点追踪成像 曲妥珠单抗 乳腺癌 心肌毒性

重庆市科卫联合中医药技术创新与应用发展项目

2020ZY023614

2024

重庆医学
重庆市卫生信息中心,重庆市医学会

重庆医学

CSTPCD
影响因子:1.797
ISSN:1671-8348
年,卷(期):2024.53(16)